orforglipron vs Semaglutide (Ozempic)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: May 2027 · NCT07613307 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)

Result source: NCT03819153

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronSemaglutide (Ozempic)
HbA1c, change-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450
Body weight, change (kg)-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
HbA1c below 7%79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484
Fasting plasma glucose, change-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
3-point MACE (% with event)—Not posted · NCT058034216.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153

HbA1c, change

orforglipron
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
Semaglutide (Ozempic)
-1.6% vs 0%−1.6 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
35 other results
  • -1.9% vs -0.1% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · primary NCT02305381
  • -1.6% vs -0.2% 1.0 mg weekly · wk 30 · n 151 · Phase 3 · primary NCT03086330
  • -1.5% vs 0% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · primary NCT02054897
  • -1.4% vs -0.1% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · primary NCT02305381
  • -1.5% vs -0.9% 1.0 mg · wk 56 · n 404 · Phase 3 · primary NCT01885208
  • -1.6% vs -0.6% 1.0 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.8% vs -1.1% 1.0 mg · wk 40 · n 300 · Phase 3 · primary NCT02648204
  • -1.6% vs -0.8% 1.0 mg/week · wk 30 · n 360 · Phase 3 · primary NCT02128932
  • -1.7% vs -1.1% 1.0 mg · wk 30 · n 290 · Phase 3 · primary NCT03191396
  • -1.3% vs -0.6% 0.5 mg weekly · wk 56 · n 409 · Phase 3 · primary NCT01930188
  • -1.5% vs -1.1% 0.5 mg · wk 40 · n 301 · Phase 3 · primary NCT02648204
  • -1.2% vs -0.8% 0.5 mg/week · wk 30 · n 362 · Phase 3 · primary NCT02128932
  • -1.5% vs -1.2% wk 52 · n 795 · Phase 3 · primary NCT03689374
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · primary NCT05514535
  • -1.4% vs -0.4% 1.0 mg · wk 104 · n 822 · Phase 3 · secondary NCT01720446
  • -1.1% vs -0.4% 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -0.9% vs -0.0% wk 104 · n 1448 · Phase 3 · secondary NCT03819153
  • -1.8% vs -0.3% 7.2 mg · wk 72 · n 288 · Phase 3 · secondary NCT05649137
  • -0.8% vs 0.2% wk 52 · n 304 · Phase 3 · secondary NCT04560998
  • -2.0% vs -0.7% 1.0 mg · wk 56 · n 204 · Phase 3 · secondary NCT02207374
  • -2.2% vs -0.7% 1.0 mg · wk 30 · n 102 · Phase 3 · secondary NCT02254291
  • -1.7% vs -0.7% 0.5 mg · wk 56 · n 220 · Phase 3 · secondary NCT02207374
  • -1.9% vs -0.7% 0.5 mg · wk 30 · n 103 · Phase 3 · secondary NCT02254291
  • -1.4% vs -0.7% wk 40 · n 276 · Phase 3 · secondary NCT05514535
  • -1.9% vs -1.1% 2.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.1% vs -0.4% 21.6 mg · wk 34 · n 59 · Phase 2 · primary NCT05144984
  • -2.1% vs -1.1% 16.0 mg · wk 40 · n 56 · Phase 2 · primary NCT05486065
  • -1.8% vs -1.1% 8.0 mg · wk 40 · n 57 · Phase 2 · primary NCT05486065
  • -2.3% vs -0.4% 2.4 mg + 2.4 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 7.2 mg · wk 34 · n 74 · Phase 2 · primary NCT05144984
  • -2.2% vs -0.4% 2.4 mg + 12.0 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -2.3% vs -0.4% 2.4 mg + 21.6 mg · wk 34 · n 77 · Phase 2 · primary NCT05144984
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
  • -1.5% vs -1.1% wk 52 · n 430 · Phase 4 · secondary NCT03596450
  • -1.4% vs -1.0% wk 104 · n 374 · Phase 4 · secondary NCT03596450

Body weight, change (kg)

orforglipron
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
Semaglutide (Ozempic)
-4.9 vs -0.6−4.3 vs placebo1.0 mg · wk 104 · n 822NCT01720446
32 other results
  • -3.6 vs -0.6 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -5.5 vs -1.4 wk 104 · n 1502 · Phase 3 · secondary NCT03819153
  • -4.7 vs -0.9 1.0 mg weekly · wk 30 · n 130 · Phase 3 · secondary NCT02054897
  • -6.4 vs -1.4 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -4.7 vs -1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -3.7 vs -0.9 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • -3.7 vs -1.4 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -14.9 vs -4.6 7.2 mg · wk 72 · n 291 · Phase 3 · secondary NCT05649137
  • -5.2 vs -1.2 wk 52 · n 310 · Phase 3 · secondary NCT04560998
  • -6.5 vs -2.3 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • -5.2 vs 1.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -4.2 vs -0.4 1.0 mg weekly · wk 30 · n 239 · Phase 3 · secondary NCT03061214
  • -5.8 vs -2 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -5.6 vs -1.9 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -6.1 vs -1.9 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -4.6 vs -2.3 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • -3.5 vs 1.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -3 vs -0.4 0.5 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -4.3 vs -1.9 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -8.0 vs 0.4 wk 40 · n 282 · Phase 3 · secondary NCT05514535
  • -4.2 vs 2.9 wk 52 · n 801 · Phase 3 · secondary NCT03689374
  • -5.7 vs -4.3 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -8.9 vs -2.3 2.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -4.7 vs -2.6 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -13.1 vs -2.3 16.0 mg · wk 40 · n 55 · Phase 2 · secondary NCT05486065
  • -10.1 vs -2.3 8.0 mg · wk 40 · n 56 · Phase 2 · secondary NCT05486065
  • -8.9 vs -2.6 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 7.2 mg · wk 34 · n 60 · Phase 2 · secondary NCT05144984
  • -10 vs -2.6 2.4 mg + 12.0 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -12 vs -2.6 2.4 mg + 21.6 mg · wk 34 · n 65 · Phase 2 · secondary NCT05144984
  • -5 vs -3.1 wk 104 · n 389 · Phase 4 · secondary NCT03596450
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352

HbA1c below 7%

orforglipron
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
Semaglutide (Ozempic)
72.3% vs 24.8%+47.5 vs placebo1.0 mg weekly · wk 30 · n 130NCT02054897
10 other results
  • 78.6% vs 10.5% 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • 82.5% vs 20.5% 1.0 mg weekly · wk 30 · n 120 · Phase 3 · secondary NCT03086330
  • 74.2% vs 24.8% 0.5 mg weekly · wk 30 · n 128 · Phase 3 · secondary NCT02054897
  • 60.6% vs 10.5% 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • 78.7% vs 52.2% 1.0 mg · wk 40 · n 300 · Phase 3 · secondary NCT02648204
  • 84% vs 49.6% 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • 80.4% vs 45.9% 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • 68.4% vs 52.2% 0.5 mg · wk 40 · n 301 · Phase 3 · secondary NCT02648204
  • 74.5% vs 49.6% 0.5 mg weekly · wk 30 · n 235 · Phase 3 · secondary NCT03061214
  • 76.1% vs 50.8% wk 52 · n 293 · Phase 3 · secondary NCT03136484

Fasting plasma glucose, change

orforglipron
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
Semaglutide (Ozempic)
-2.1 vs -0.9−1.2 vs placebo1.0 mg · wk 104 · n 822NCT01720446
24 other results
  • -1.8 vs -0.9 0.5 mg · wk 104 · n 826 · Phase 3 · secondary NCT01720446
  • -2.4 vs -0.6 1.0 mg weekly · wk 30 · n 129 · Phase 3 · secondary NCT02054897
  • -2.4 vs -0.5 1.0 mg weekly · wk 30 · n 131 · Phase 3 · secondary NCT02305381
  • -2.3 vs 0.1 1.0 mg weekly · wk 30 · n 151 · Phase 3 · secondary NCT03086330
  • -2.4 vs -0.6 0.5 mg weekly · wk 30 · n 125 · Phase 3 · secondary NCT02054897
  • -1.6 vs -0.5 0.5 mg weekly · wk 30 · n 132 · Phase 3 · secondary NCT02305381
  • -3.3 vs -1.1 7.2 mg · wk 72 · n 281 · Phase 3 · secondary NCT05649137
  • -2.8 vs -2 1.0 mg · wk 56 · n 404 · Phase 3 · secondary NCT01885208
  • -2.6 vs -1.1 1.0 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.8 vs -1.9 1.0 mg · wk 40 · n 299 · Phase 3 · secondary NCT02648204
  • -2.7 vs -2.1 1.0 mg/week · wk 30 · n 360 · Phase 3 · secondary NCT02128932
  • -2.6 vs -1 1.0 mg weekly · wk 30 · n 238 · Phase 3 · secondary NCT03061214
  • -2.6 vs -1.5 1.0 mg · wk 30 · n 290 · Phase 3 · secondary NCT03191396
  • -2.1 vs -1.1 0.5 mg weekly · wk 56 · n 409 · Phase 3 · secondary NCT01930188
  • -2.2 vs -1.9 0.5 mg · wk 40 · n 298 · Phase 3 · secondary NCT02648204
  • -2.0 vs -2.1 0.5 mg/week · wk 30 · n 362 · Phase 3 · secondary NCT02128932
  • -1.3 vs -0.8 wk 52 · n 770 · Phase 3 · secondary NCT03689374
  • -2.2 vs -1 0.5 mg weekly · wk 30 · n 237 · Phase 3 · secondary NCT03061214
  • -2.5 vs -2 wk 52 · n 394 · Phase 3 · secondary NCT03136484
  • -1.4 vs -0.1 21.6 mg · wk 34 · n 43 · Phase 2 · secondary NCT05144984
  • -3.9 vs -0.1 2.4 mg + 2.4 mg · wk 34 · n 61 · Phase 2 · secondary NCT05144984
  • -3.4 vs -0.1 2.4 mg + 7.2 mg · wk 34 · n 58 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 12.0 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984
  • -3.8 vs -0.1 2.4 mg + 21.6 mg · wk 34 · n 63 · Phase 2 · secondary NCT05144984

3-point MACE (% with event)

orforglipron
—Not posted · NCT05803421
Semaglutide (Ozempic)
6.6% vs 8.9%−2.3 vs placebon 1648NCT01720446
1 other result
  • 12% vs 14.4% n 1767 · Phase 3 · secondary NCT03819153
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety

Coverage. orforglipron: 16 of 16 rows · Semaglutide (Ozempic): 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Rows use multiple source trials
Semaglutide (Ozempic)
Rows use multiple source trials
BMI
absolute change · kg
No placebo or comparator arm
-2.5 kg @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.9 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-0.7 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.5 kg @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
-2.1 kg @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.13% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.97% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.71% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.23% (n=91) @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-0.86% (n=335) @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
90.82% (n=125) @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
86.11% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
82.73% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
67.6% (n=480) @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
57.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
68.91% (n=119) vs 18.56% (n=97) placebo @ 40wk36 mga,e,b,c
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
68.75% (n=112) vs 18.56% (n=97) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
66.39% (n=119) vs 18.56% (n=97) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
66.7% (n=300) vs 34.1% (n=299) Dulaglutide @ 40wk1.0 mga,e,b,c
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
49.2% (n=301) vs 34.1% (n=299) Dulaglutide @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
No placebo or comparator arm
84.56% (n=125) @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
76.23% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
62.64% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
51.7% (n=480) @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
38.5% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
SBP
absolute change · mmHg
-6 vs -0.5 placebo mmHg @ 40wk36 mga,f,c,g
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
-6.1 vs -0.5 placebo mmHg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-3.2 vs -0.5 placebo mmHg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-3.9 vs -1.4 placebo mmHg @ 104wkf,c,g
NCT03819153 · Phase 3
1 other source trial
-3 vs -2.8 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
Waist Circumference Change
absolute change · cm
No placebo or comparator arm
-6.5 cm @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-4.6 cm @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.4 cm @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-5.9 cm @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
-5.2 cm @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Weight
percent change · % of baseline
-9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mgb,c
NCT05872620 · Phase 3 · sponsor-reported, not registry data
-13.5% (n=291) vs -4% (n=95) placebo @ 72wk7.2 mgb,c
NCT05649137 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-6.75 kg @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-5.08 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.81 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-3.85 kg @ 52wkb,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
-3.77 kg @ 52wk
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
Weight Loss 10%
responder rate · % of participants
No placebo or comparator arm
37.91% (n=125) @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
24.68% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
10.11% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
28.4% (n=480) @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
22.6% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Weight Loss 5%
responder rate · % of participants
66.39% (n=119) vs 14.58% (n=96) placebo @ 40wk36 mga,e,b,c
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
58.56% (n=111) vs 14.58% (n=96) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
47.06% (n=119) vs 14.58% (n=96) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
63% (n=300) vs 22.7% (n=299) Dulaglutide @ 40wk1.0 mga,e,b,c
NCT02648204 · Phase 3 · registry result, not featured evidence
show 1 more dose
43.9% (n=301) vs 22.7% (n=299) Dulaglutide @ 40wk0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
65.14% (n=125) @ 52wk36 mga,b,c,d
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
49.52% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
27% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
59.2% (n=480) @ 40wk2.0 mg weeklya,b,c,d
NCT03989232 · Phase 3
show 1 more dose
51.3% (n=481) @ 40wk1.0 mg weekly
NCT03989232 · Phase 3
Dropout rate
6.7%36 mgh
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
5.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
5.3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3.5%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
8.8%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
6.3%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
7.4%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
11.8%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.7%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
7.8%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
57.1%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
1.3%1.0 mgi
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
1.7%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.4%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
7.8%0.5 mg weekly
NCT02054897 · Phase 3
5.1%1.0 mg weekly
NCT01930188 · Phase 3 · combination
5.4%0.5 mg weekly
NCT01930188 · Phase 3 · combination
5.3%1.0 mg/week
NCT02128932 · Phase 3
7.5%0.5 mg/week
NCT02128932 · Phase 3
3.8%2.0 mg weekly
NCT03989232 · Phase 3
2.1%1.0 mg weekly
NCT03989232 · Phase 3
3.8%1.0 mg weekly
NCT02305381 · Phase 3
3.8%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
10.6%
NCT05533632 · Phase 4 · registry result, not featured evidence
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
28.1%
NCT03596450 · Phase 4 · registry result, not featured evidence
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
1.7%Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
3.9%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
18.3%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
7.6%
NCT04560998 · Phase 3 · registry result, not featured evidence
1.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
9.7%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
8.7%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.9%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
2.6%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
7.3%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
4.1%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.5%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2.9%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
8.2%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
11.3%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
12.9%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
3.9%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
3.9%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.7%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
2.2%36 mgh
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
4.4%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.5%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.4%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0.7%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.6%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
35.7%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
—1.0 mgi
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
—0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT03819153 · Phase 3
—1.0 mg weekly
NCT02054897 · Phase 3
—0.5 mg weekly
NCT02054897 · Phase 3
—1.0 mg weekly
NCT01930188 · Phase 3 · combination
—0.5 mg weekly
NCT01930188 · Phase 3 · combination
—1.0 mg/week
NCT02128932 · Phase 3
—0.5 mg/week
NCT02128932 · Phase 3
—2.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT03989232 · Phase 3
—1.0 mg weekly
NCT02305381 · Phase 3
—0.5 mg weekly
NCT02305381 · Phase 3
—
NCT04126603 · Phase 4 · registry result, not featured evidence
—
NCT05786521 · Phase 4 · registry result, not featured evidence
3.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
2.2%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
—
NCT04560998 · Phase 3 · registry result, not featured evidence
—
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
NCT03689374 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
—
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
—1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
—1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
0%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
0%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
—1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
—2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
—21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
—2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
—2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
4.5%36 mgh
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
2.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.8%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.1%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.6%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2.9%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
1.8%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
5.9%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.1%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
33.6%1.0 mgi
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 47 more results
35%0.5 mg
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
9.4%1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—1.0 mg
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
49.6%
NCT03819153 · Phase 3
5.4%1.0 mg weekly
NCT02054897 · Phase 3
5.5%0.5 mg weekly
NCT02054897 · Phase 3
7.3%1.0 mg weekly
NCT01930188 · Phase 3 · combination
7.3%0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.7%1.0 mg/week
NCT02128932 · Phase 3
6.1%0.5 mg/week
NCT02128932 · Phase 3
4.4%2.0 mg weekly
NCT03989232 · Phase 3
5.2%1.0 mg weekly
NCT03989232 · Phase 3
9.2%1.0 mg weekly
NCT02305381 · Phase 3
6.1%0.5 mg weekly
NCT02305381 · Phase 3
0%
NCT04126603 · Phase 4 · registry result, not featured evidence
0%
NCT05786521 · Phase 4 · registry result, not featured evidence
1%
NCT05533632 · Phase 4 · registry result, not featured evidence
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
6%
NCT03596450 · Phase 4 · registry result, not featured evidence
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
5.9%INSULIN GLARGINE (REDUCED) + SEMAG
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
—Insuline Glargine U100 (Reduced) +
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
9.8%7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
19.7%1.0 mg
NCT04865770 · Phase 3 · registry result, not featured evidence
18.7%
NCT04560998 · Phase 3 · registry result, not featured evidence
6.2%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
7.4%
NCT03689374 · Phase 3 · registry result, not featured evidence
6.6%1.0 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
6.3%0.5 mg weekly
NCT03061214 · Phase 3 · registry result, not featured evidence
4.6%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
5.9%1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
4.7%1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
7.7%1.0 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5.6%0.5 mg
NCT02648204 · Phase 3 · registry result, not featured evidence
5%1.0 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
7.9%0.5 mg
NCT02207374 · Phase 3 · registry result, not featured evidence
2%1.0 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
5.8%0.5 mg
NCT02254291 · Phase 3 · registry result, not featured evidence
6.7%2.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
1.6%16.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.3%8.0 mg
NCT05486065 · Phase 2 · registry result, not featured evidence
3.4%21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence
2.6%2.4 mg + 12.0 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
7.8%2.4 mg + 2.4 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
6.5%2.4 mg + 21.6 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
4.1%2.4 mg + 7.2 mg
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
36 mgh
constipation 29.1%
nausea 27.6%
nasopharyngitis 16.4%
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
12 mg
constipation 30.4%
nasopharyngitis 22.2%
nausea 19.3%
NCT06010004 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 17.4%
constipation 16.7%
nausea 12.9%
NCT06010004 · Phase 3 · registry result, not featured evidence
36 mg
diarrhoea 25.5% (placebo 9.4%)
diabetic retinopathy 17% (placebo 15.2%)
nausea 17% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
12 mg
diarrhoea 21.2% (placebo 9.4%)
dyspepsia 21.2% (placebo 7.2%)
nausea 19% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
3 mg
diarrhoea 18.9% (placebo 9.4%)
diabetic retinopathy 14.7% (placebo 15.2%)
nausea 12.6% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
36 mg
nausea 37% (placebo 5.5%)
vomiting 33.3% (placebo 1.8%)
diarrhoea 25.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
36 mg
nausea 26.5% (placebo 5.5%)
vomiting 20.6% (placebo 1.8%)
eructation 8.8% (placebo 0%)
NCT05048719 · Phase 2 · registry result, not featured evidence
12 mg
nausea 37.5% (placebo 5.5%)
vomiting 21.4% (placebo 1.8%)
diarrhoea 16.1% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 23.5% (placebo 5.5%)
diarrhoea 21.6% (placebo 7.3%)
constipation 13.7% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
vomiting 35.5% (placebo 1.8%)
diarrhoea 29% (placebo 7.3%)
nausea 29% (placebo 5.5%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 28.1% (placebo 7.3%)
nausea 25% (placebo 5.5%)
vomiting 21.9% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
24 mg
nausea 34% (placebo 5.5%)
vomiting 27.7% (placebo 1.8%)
diarrhoea 14.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 55.6% (placebo 25%)
constipation 33.3% (placebo 0%)
vomiting 22.2% (placebo 25%)
NCT05086445 · Phase 1 · registry result, not featured evidence
2 mg
vomiting 40% (placebo 25%)
nausea 30% (placebo 25%)
abdominal distension 20% (placebo 0%)
NCT05086445 · Phase 1 · registry result, not featured evidence
3/6/12/15 mg QD
nausea 50% (placebo 5.9%)
vomiting 50% (placebo 0%)
decreased appetite 40% (placebo 11.8%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21 mg QD
nausea 42.9% (placebo 5.9%)
decreased appetite 28.6% (placebo 11.8%)
covid-19 21.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21/27 mg QD
decreased appetite 55.6% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
nausea 33.3% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9 mg QD
vomiting 55.6% (placebo 0%)
decreased appetite 44.4% (placebo 11.8%)
nausea 44.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9/21/36/45 mg QD
nausea 77.8% (placebo 5.9%)
decreased appetite 66.7% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
NCT04426474 · Phase 1 · registry result, not featured evidence
1.0 mgi
nausea 21.8% (placebo 7.5%)
diarrhoea 18% (placebo 11.8%)
vomiting 14.8% (placebo 5.1%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 42 more results
0.5 mg
diarrhoea 17.9% (placebo 11.8%)
nausea 17.3% (placebo 7.5%)
lipase increased 11.4% (placebo 8%)
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
1.0 mg
nausea 22.3%
diarrhoea 11.4%
lipase increased 10.1%
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
diabetic retinopathy 19.2% (placebo 18.4%)
covid-19 12.5% (placebo 13.9%)
NCT03819153 · Phase 3
1.0 mg weekly
nausea 23.8% (placebo 7.8%)
diarrhoea 10.8% (placebo 2.3%)
headache 6.9% (placebo 6.2%)
NCT02054897 · Phase 3
0.5 mg weekly
nausea 20.3% (placebo 7.8%)
diarrhoea 12.5% (placebo 2.3%)
headache 11.7% (placebo 6.2%)
NCT02054897 · Phase 3
1.0 mg weekly
nausea 17.6%
diarrhoea 13%
vomiting 10%
NCT01930188 · Phase 3 · combination
0.5 mg weekly
nausea 17.8%
diarrhoea 13%
nasopharyngitis 12.2%
NCT01930188 · Phase 3 · combination
1.0 mg/week
nausea 22.2%
diarrhoea 19.2%
vomiting 10.3%
NCT02128932 · Phase 3
0.5 mg/week
nausea 21.3%
diarrhoea 16.3%
nasopharyngitis 12.4%
NCT02128932 · Phase 3
2.0 mg weekly
nausea 14.4%
diarrhoea 9.4%
vomiting 7.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 14.6%
diarrhoea 8.8%
vomiting 6.7%
NCT03989232 · Phase 3
1.0 mg weekly
nausea 16.8% (placebo 4.5%)
vomiting 11.5% (placebo 3%)
diarrhoea 6.9% (placebo 1.5%)
NCT02305381 · Phase 3
0.5 mg weekly
nausea 11.4% (placebo 4.5%)
lipase increased 9.1% (placebo 3%)
nasopharyngitis 8.3% (placebo 10.5%)
NCT02305381 · Phase 3
abdominal pain 60%
NCT05786521 · Phase 4 · registry result, not featured evidence
nausea 11.5%
diarrhea 5.8%
NCT05533632 · Phase 4 · registry result, not featured evidence
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nausea 18.4%
diarrhoea 13.5%
vomiting 9.7%
NCT05514535 · Phase 3 · registry result, not featured evidence · combination
7.2 mg
nausea 29% (placebo 11.8%)
diarrhoea 18.2% (placebo 8.8%)
vomiting 16.6% (placebo 2.9%)
NCT05649137 · Phase 3 · registry result, not featured evidence
1.0 mg
covid-19 5.6% (placebo 0%)
decreased appetite 5.6% (placebo 0%)
diabetic retinopathy 5.6% (placebo 5.7%)
NCT04865770 · Phase 3 · registry result, not featured evidence
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3 · registry result, not featured evidence
covid-19 14.4%
diarrhoea 12.1%
nausea 11.5%
NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nausea 14.8%
diarrhoea 7.4%
nasopharyngitis 6.5%
NCT03689374 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
diarrhoea 16.9%
nausea 13.4%
upper respiratory tract infection 13.1%
NCT03061214 · Phase 3 · registry result, not featured evidence
0.5 mg weekly
diarrhoea 20.2%
upper respiratory tract infection 9.8%
lipase increased 7.7%
NCT03061214 · Phase 3 · registry result, not featured evidence
nausea 22.7%
diarrhoea 15.1%
vomiting 12.8%
NCT03136484 · Phase 3 · registry result, not featured evidence · combination
1.0 mg
nausea 21.5%
diarrhoea 15.6%
decreased appetite 10.4%
NCT03191396 · Phase 3 · registry result, not featured evidence
1.0 mg weekly
nausea 19.3% (placebo 3.3%)
diarrhoea 11.3% (placebo 6%)
vomiting 9.3% (placebo 2%)
NCT03086330 · Phase 3 · registry result, not featured evidence
1.0 mg
nausea 21%
diarrhoea 13.7%
vomiting 10.3%
NCT02648204 · Phase 3 · registry result, not featured evidence
0.5 mg
nausea 22.3%
diarrhoea 14.3%
vomiting 10%
NCT02648204 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 31.1%
nausea 19.1%
diarrhoea 15.8%
NCT02207374 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 33.9%
constipation 18.4%
nausea 12.1%
NCT02207374 · Phase 3 · registry result, not featured evidence
1.0 mg
nasopharyngitis 17.6%
nausea 12.7%
constipation 11.8%
NCT02254291 · Phase 3 · registry result, not featured evidence
0.5 mg
nasopharyngitis 16.5%
constipation 14.6%
nausea 10.7%
NCT02254291 · Phase 3 · registry result, not featured evidence
2.0 mg
nausea 21.7% (placebo 15.3%)
vomiting 18.3% (placebo 6.8%)
diarrhoea 15% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
16.0 mg
nausea 37.1% (placebo 15.3%)
vomiting 25.8% (placebo 6.8%)
diarrhoea 21% (placebo 11.9%)
NCT05486065 · Phase 2 · registry result, not featured evidence
8.0 mg
nausea 41.7% (placebo 15.3%)
diarrhoea 33.3% (placebo 11.9%)
vomiting 23.3% (placebo 6.8%)
NCT05486065 · Phase 2 · registry result, not featured evidence
21.6 mg
injection site erythema 10.2% (placebo 0%)
injection site reaction 10.2% (placebo 0%)
diarrhoea 8.5% (placebo 11.5%)
NCT05144984 · Phase 2 · registry result, not featured evidence
2.4 mg + 12.0 mg
diarrhoea 14.3% (placebo 11.5%)
constipation 9.1% (placebo 1.6%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 2.4 mg
nausea 19.5% (placebo 1.6%)
diarrhoea 14.3% (placebo 11.5%)
covid-19 7.8% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 21.6 mg
diarrhoea 13% (placebo 11.5%)
nausea 13% (placebo 1.6%)
covid-19 11.7% (placebo 13.1%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination
2.4 mg + 7.2 mg
diarrhoea 21.6% (placebo 11.5%)
lipase increased 12.2% (placebo 3.3%)
nausea 12.2% (placebo 1.6%)
NCT05144984 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 40 weeks versus 52 weeks.
  5. eThe reported result categories differ.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 104 weeks versus 40 weeks.
  8. hPopulation comparability has not been reviewed for these studies.
  9. iPopulation comparability has not been reviewed for 43 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

HbA1c Less Than 5 7 30.51% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
21.92% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
7.7% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -64.5 mg @ 52wk36 mg
absolute change · mg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-55.1 mg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-51.7 mg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 15% 20.94% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
13.96% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.79% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -82.27 mg/dL @ 52wk36 mg
absolute change · mg/dL
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-73.14 mg/dL @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-66.32 mg/dL @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -37.8 vs -1.1 placebo mg @ 40wk36 mg
absolute change · mg
NCT05971940 · Phase 3 · registry result, not featured evidence
show 7 more results
-53.9 vs -11.1 placebo mg @ 26wk36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-37.4 vs -1.1 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-53.7 vs -11.1 placebo mg @ 26wk12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-30.6 vs -1.1 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-32.6 vs -11.1 placebo mg @ 26wk3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-55.9 vs -11.1 placebo mg @ 26wk45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-52.2 vs -11.1 placebo mg @ 26wk24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
Non-HDL-C -7.91% (n=137) vs 3.19% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.8% (n=131) vs 3.19% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-1.82% (n=136) vs 3.19% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Triglycerides -14% (n=136) vs 0% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-16.5% (n=130) vs 0% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-9.1% (n=136) vs 0% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -58.1 vs -17.6 placebo mg @ 40wk36 mg
absolute change · mg
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-56 vs -17.6 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-43.6 vs -17.6 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 6 5 79.39% (n=57) vs 14.56% (n=22) placebo @ 26wk36 mg
responder rate · % of participants
NCT05048719 · Phase 2 · registry result, not featured evidence
show 4 more results
70.73% (n=49) vs 14.56% (n=22) placebo @ 26wk12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
45.3% (n=46) vs 14.56% (n=22) placebo @ 26wk3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
83.52% (n=58) vs 14.56% (n=22) placebo @ 26wk45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
80.12% (n=42) vs 14.56% (n=22) placebo @ 26wk24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
Fasting Insulin -12.2 vs -9.71 placebo L @ 12wk3/6/12/21 mg QD
absolute change · L
NCT04426474 · Phase 1 · registry result, not featured evidence
show 4 more results
-5.46 vs -9.71 placebo L @ 12wk3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
15.16 vs -9.71 placebo L @ 12wk3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
7.3 vs -9.71 placebo L @ 12wk3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
-1.32 vs -9.71 placebo L @ 12wk3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence

Semaglutide (Ozempic)

MACE 3-point Composite 6.6% (n=1648) vs 8.9% (n=1649) placebo
event count · % of participants
NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3
show 1 more result
12% (n=1767) vs 14.4% (n=1766) placebo*
NCT03819153 · Phase 3 · converted to % from 212 Participants as posted
HbA1c 6.5 or Less 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk1.0 mg
event count · % of participants
NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted
Chronic Dialysis 4.9% (n=1767) vs 5.7% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 87 Participants as posted
Renal Death 0.3% (n=1767) vs 0.3% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 5 Participants as posted
UACR 0.6 vs 0.89 placebo ratio @ 104wk
ratio to baseline · ratio
NCT03819153 · Phase 3
Non-fatal MI 2.9% (n=1767) vs 3.6% (n=1766) placebo
event count · % of participants
NCT03819153 · Phase 3 · converted to % from 52 Participants as posted
MALE 0.9% (n=1767) vs 1.6% (n=1766) placebo
event rate · % of participants
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
Acute Limb Ischemia 0.1% (n=1767) vs 0.2% (n=1766) placebo @ 234wk
event rate · % of participants
Acute limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 1 Participants as posted
Chronic Limb Ischemia Hospitalization 0.9% (n=1767) vs 1.4% (n=1766) placebo @ 234wk
event count · % of participants
Chronic limb ischaemia hospitalization
NCT03819153 · Phase 3 · converted to % from 16 Participants as posted
DBP -0.98 vs -1.44 Insulin Glargine mmHg @ 30wk1.0 mg/week
absolute change · mmHg
NCT02128932 · Phase 3
show 7 more results
-1.5 vs -1.3 Liraglutide mmHg @ 30wk1.0 mg
NCT03191396 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.1 placebo mmHg @ 30wk1.0 mg weekly
NCT03086330 · Phase 3 · registry result, not featured evidence
-1.38 vs -1.44 Insulin Glargine mmHg @ 30wk0.5 mg/week
NCT02128932 · Phase 3
-3 vs -3 placebo mmHg @ 72wk7.2 mg
NCT05649137 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.8 placebo mmHg @ 104wk
NCT03819153 · Phase 3
-1.6 vs -0.9 Standard of Care mmHg @ 52wk
NCT03596450 · Phase 4 · registry result, not featured evidence
-1.9 vs -1.4 Standard of Care mmHg @ 104wk
NCT03596450 · Phase 4 · registry result, not featured evidence
SBP -5.61 vs -2.29 Sitagliptin mmHg @ 56wk1.0 mg weekly
absolute change · mmHg
Systolic blood pressure
NCT01930188 · Phase 3 · combination
show 1 more result
-5.07 vs -2.29 Sitagliptin mmHg @ 56wk0.5 mg weekly
Systolic blood pressure
NCT01930188 · Phase 3 · combination
DTSQs 5.91 vs 4.45 Sitagliptin score @ 56wk1.0 mg weekly
absolute change · score
NCT01930188 · Phase 3 · combination
show 4 more results
5.37 vs 3.99 Insulin Glargine score @ 30wk1.0 mg/week
NCT02128932 · Phase 3
5.28 vs 4.45 Sitagliptin score @ 56wk0.5 mg weekly
NCT01930188 · Phase 3 · combination
4.86 vs 3.99 Insulin Glargine score @ 30wk0.5 mg/week
NCT02128932 · Phase 3
4.56 vs 2.17 Insuline Glargine U100 (Titrated) score @ 40wk
NCT05514535 · Phase 3 · registry result, not featured evidence · combination

+ 103 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07223593 (registry estimate)

No aligned efficacy figure on record for this race.

Semaglutide (Ozempic)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01720446 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).

Next expected readout: July 2028 · NCT07073053 (registry estimate)

Reported efficacy

Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)

Result source: NCT04560998

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronSemaglutide (Ozempic)
LDL-C, % change—Trial running · NCT07223593—Not reported
Non-HDL-C, % change—Trial running · NCT07223593—Not reported
ApoB, % change—Trial running · NCT07223593—Not reported
Lp(a), % change—Trial running · NCT07223593—Not reported
3-point MACE (% with event)—Trial running · NCT07223593—Not reported

LDL-C, % change

orforglipron
—Trial running · NCT07223593
Semaglutide (Ozempic)
—Not reported

Non-HDL-C, % change

orforglipron
—Trial running · NCT07223593
Semaglutide (Ozempic)
—Not reported

ApoB, % change

orforglipron
—Trial running · NCT07223593
Semaglutide (Ozempic)
—Not reported

Lp(a), % change

orforglipron
—Trial running · NCT07223593
Semaglutide (Ozempic)
—Not reported

3-point MACE (% with event)

orforglipron
—Trial running · NCT07223593
Semaglutide (Ozempic)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

orforglipron: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. orforglipron: 0 of 4 rows · Semaglutide (Ozempic): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Ozempic)
Dropout rate
7.6%a
NCT04560998 · Phase 3
Discontinued due to AEs
—a
NCT04560998 · Phase 3
Serious AEs
18.7%a
NCT04560998 · Phase 3
Most frequent reported AEs
a
covid-19 7.6% (placebo 5.3%)
nausea 5.6% (placebo 0.8%)
NCT04560998 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Ozempic)

Max Walking Distance 1.21 vs 1.08 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.16 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
VascuQoL-6 2 vs 1 placebo score @ 52wk
absolute change · score
NCT04560998 · Phase 3
Pain-free Walking Distance 1.21 vs 1.1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
show 1 more result
1.18 vs 1.1 placebo ratio @ 57wk
NCT04560998 · Phase 3
HbA1c -0.8% (n=304) vs 0.2% (n=311) placebo @ 52wk
absolute change · percentage points
NCT04560998 · Phase 3
Weight -5.2 vs -1.2 placebo kg @ 52wk
absolute change · kg
NCT04560998 · Phase 3
SBP -4 vs -1 placebo mmHg @ 52wk
absolute change · mmHg
NCT04560998 · Phase 3
Total Cholesterol 0.96 vs 1 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
LDL Cholesterol 0.99 vs 1.03 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
HDL Cholesterol 1.04 vs 0.99 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
Triglyceride 0.8 vs 0.95 placebo ratio @ 52wk
ratio to baseline · ratio
NCT04560998 · Phase 3
ABI 1.06 vs 1.02 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3
TBI 1.07 vs 1.04 placebo ratio @ 52wk
absolute change · ratio
NCT04560998 · Phase 3

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Ozempic)'s landscape